Overview

Safety and Efficacy of Autologous Mesenchymal Stem Cells in Chronic Spinal Cord Injury

Status:
Terminated
Trial end date:
2021-03-04
Target enrollment:
Participant gender:
Summary
This phase II/III clinical trial is designed to evaluate the safety and efficacy of autologous Mesenchymal Stem Cells (MSC) transplanted directly into the injured spinal cord.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Pharmicell Co., Ltd.